CHM 0.00% 1.4¢ chimeric therapeutics limited

Ann: First patient dosed in Phase 1/2 trial of CHM CDH17, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 12,712 Posts.
    lightbulb Created with Sketch. 3878
    It takes at least 35 days to determine whether it is safe to progress or not. Maybe 5 patients dose 1, then 5 dose 2, then 5 dose 3. If IMU is a guide to go by then it probably will take 2 years before ph2. Would be nice to get some " early signals " - updates but that will take at least the first dose to be completed.

    Unless CDH 17 is so powerful and safe that patients come out with a scan showing zero signs of cancer within weeks. But the big unknown is how much has the cancer already progressed and how much damage suffered the organs. If they have been given patients who are close to death then we could see the same dilemma that IMU's Her-Vaxx in its combo trial ph 2 suffered, patients dying closely after dosing or even before. Plus, what will be the interaction of chemo and CDH17 and the immune system.

    If I would make the rules CDH 17 would be given as a mono treatment to see the real impact as all previous treatments have already failed. But as everyone tries to keep off " law suit hungry lawyers and advocates " the old way continues.

    GLTA
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.